[go: up one dir, main page]

ZA916770B - Nonaqueous fluorinated drug delivery vehicle suspensions - Google Patents

Nonaqueous fluorinated drug delivery vehicle suspensions

Info

Publication number
ZA916770B
ZA916770B ZA916770A ZA916770A ZA916770B ZA 916770 B ZA916770 B ZA 916770B ZA 916770 A ZA916770 A ZA 916770A ZA 916770 A ZA916770 A ZA 916770A ZA 916770 B ZA916770 B ZA 916770B
Authority
ZA
South Africa
Prior art keywords
nonaqueous
drug delivery
delivery vehicle
pharmaceutical compositions
vehicle suspensions
Prior art date
Application number
ZA916770A
Other languages
English (en)
Inventor
David Louis Meadows
Louis Meadows David
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of ZA916770B publication Critical patent/ZA916770B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA916770A 1990-09-27 1991-08-27 Nonaqueous fluorinated drug delivery vehicle suspensions ZA916770B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/588,697 US5173298A (en) 1990-09-27 1990-09-27 Nonaqueous fluorinated drug delivery vehicle suspensions

Publications (1)

Publication Number Publication Date
ZA916770B true ZA916770B (en) 1992-04-29

Family

ID=24354930

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA916770A ZA916770B (en) 1990-09-27 1991-08-27 Nonaqueous fluorinated drug delivery vehicle suspensions

Country Status (16)

Country Link
US (1) US5173298A (fr)
EP (1) EP0550615B1 (fr)
JP (1) JP3253072B2 (fr)
KR (1) KR100195760B1 (fr)
AT (1) ATE125696T1 (fr)
AU (1) AU656919B2 (fr)
CA (1) CA2090404C (fr)
DE (1) DE69111821T2 (fr)
ES (1) ES2075468T3 (fr)
IE (1) IE69016B1 (fr)
IL (1) IL99290A (fr)
NZ (1) NZ239558A (fr)
PT (1) PT99108B (fr)
TW (1) TW224428B (fr)
WO (1) WO1992005770A1 (fr)
ZA (1) ZA916770B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048857A (en) * 1989-10-17 2000-04-11 Ellinwood, Jr.; Everett H. Dosing method of administering medicaments via inhalation administration
US5660851A (en) * 1989-12-26 1997-08-26 Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem Ocular inserts
IE67185B1 (en) * 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
DE69129696T2 (de) * 1990-04-27 1999-02-25 Allergan, Inc., Irvine, Calif. Polymeres arzneimittelabgabesystem
DE4201079C3 (de) * 1992-01-17 1997-09-11 Gramer Eugen Kombinationspräparate zur Augeninnendrucksenkung
AU3924193A (en) * 1992-03-19 1993-10-21 Allergan, Inc. Compositions comprising a drug delivery vehicle suspended in a nonaqueous fluorinated liquid
EP0679088B1 (fr) 1992-09-29 2002-07-10 Inhale Therapeutic Systems Liberation dans les poumons de fragments actifs d'hormone parathyroidienne
US5336487A (en) * 1993-03-05 1994-08-09 Refojo Miguel F Method of treating eye disorders with silicon/fluorosilicone copolymer oil
AU692852B2 (en) 1994-03-04 1998-06-18 University Of Washington Block and graft copolymers and methods relating thereto
DE4414755C2 (de) * 1994-04-27 2000-11-16 Lohmann Therapie Syst Lts Kollagenzubereitung zur gesteuerten Abgabe von Wirkstoffen, Verfahren und Verwendung
US5661029A (en) * 1994-05-12 1997-08-26 Biomed Biological culture growth and observation device
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US5503869A (en) * 1994-10-21 1996-04-02 Glaxo Wellcome Inc. Process for forming medicament carrier for dry powder inhalator
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
WO1996035467A1 (fr) * 1995-05-12 1996-11-14 Genentech, Inc. Administration d'un aerosol constitue de particules de grandes dimensions, contenant un produit a usage biologique
US5667809A (en) * 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US5874469A (en) * 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
US5861175A (en) 1996-03-15 1999-01-19 Alliance Pharmaceutical Corp. Use of fluorocarbons for diagnosis and treatment of articular disorders
EP1616563A3 (fr) * 1996-05-24 2006-01-25 Angiotech Pharmaceuticals, Inc. Administration périvasculaire de facteurs anti-angiogéniques pour le traitement ou la prévention des maladies vasculaires
US20030077317A1 (en) * 1996-06-25 2003-04-24 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
US5955096A (en) * 1996-06-25 1999-09-21 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
GB9816724D0 (en) * 1998-08-01 1998-09-30 Boots Co Plc Therapeutic agents
WO2000050016A2 (fr) * 1999-02-23 2000-08-31 Angiotech Pharmaceuticals, Inc. Compositions et methodes pour l'amelioration de l'integrite de cavites et de passages corporels affaiblis
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7442388B2 (en) 2000-05-10 2008-10-28 Weers Jeffry G Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
WO2002064114A1 (fr) * 2001-02-15 2002-08-22 Sanwa Kagaku Kenkyusho Co., Ltd. Nouvelles compositions ophtalmiques
PT1458360E (pt) 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
JP5466350B2 (ja) 2003-03-03 2014-04-09 ダイアックス、コープ ＨＧＦレセプター（ｃＭｅｔ）を特異的に結合するペプチドおよびその使用
US20050118124A1 (en) * 2003-12-01 2005-06-02 Reinhart Gale M. Compositions for treating keratinous surfaces
US20050288197A1 (en) * 2004-06-08 2005-12-29 Ocularis Pharma, Inc. Silicone polymer topical eye compositions and methods of use
US8153435B1 (en) 2005-03-30 2012-04-10 Tracer Detection Technology Corp. Methods and articles for identifying objects using encapsulated perfluorocarbon tracers
US20070219127A1 (en) * 2006-03-20 2007-09-20 Walt John G Cyclosporin a compositions
EP2207570A2 (fr) 2007-09-14 2010-07-21 Nitto Denko Corporation Vecteurs de médicament
US9057712B1 (en) 2011-10-27 2015-06-16 Copilot Ventures Fund Iii Llc Methods of delivery of encapsulated perfluorocarbon taggants

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3911138B1 (en) * 1973-02-26 1996-10-29 Childrens Hosp Medical Center Artificial blood and method for supporting oxygen transport in animals
US4105798A (en) * 1976-07-19 1978-08-08 Sun Ventures, Inc. Perfluoro polycyclic compounds for use as synthetic blood and perfusion media
US4115544A (en) * 1976-08-18 1978-09-19 Alza Corporation Ocular system made of bioerodible esters having linear ether
WO1981000002A1 (fr) * 1979-06-25 1981-01-08 Suntech Utilisation de carbone perfluore pour le traitement des brulures
US4452818A (en) * 1982-03-19 1984-06-05 Haidt Sterling J Extraocular method of treating the eye with liquid perfluorocarbons
GR78151B (fr) * 1982-04-05 1984-09-26 Alcon Lab Inc
US4649047A (en) * 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
US4879304A (en) * 1987-05-01 1989-11-07 Angelini Pharmaceuticals Ltd. Ophthalmic compositions and process for preparing
US4882150A (en) * 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US4865846A (en) * 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
FR2643572A1 (fr) * 1988-12-22 1990-08-31 Rhone Poulenc Chimie Procede d'encapsulation de particules par pelliculage au moyen d'un copolymere silicone thermoplastique

Also Published As

Publication number Publication date
CA2090404A1 (fr) 1992-03-28
KR100195760B1 (ko) 1999-06-15
JP3253072B2 (ja) 2002-02-04
EP0550615A1 (fr) 1993-07-14
IE913379A1 (en) 1992-04-08
US5173298A (en) 1992-12-22
CA2090404C (fr) 2001-11-20
IL99290A0 (en) 1992-07-15
JPH06501258A (ja) 1994-02-10
DE69111821D1 (de) 1995-09-07
IL99290A (en) 1996-09-12
WO1992005770A1 (fr) 1992-04-16
TW224428B (fr) 1994-06-01
AU656919B2 (en) 1995-02-23
IE69016B1 (en) 1996-07-24
ATE125696T1 (de) 1995-08-15
NZ239558A (en) 1993-10-26
EP0550615B1 (fr) 1995-08-02
PT99108B (pt) 1999-02-26
ES2075468T3 (es) 1995-10-01
DE69111821T2 (de) 1995-12-14
PT99108A (pt) 1993-11-30
AU8644291A (en) 1992-04-28

Similar Documents

Publication Publication Date Title
IL99290A0 (en) Nonaqueous fluorinated drug delivery vehicle suspensions
DE3764253D1 (de) Medizinischer saugkoerper mit roentgenkontrastmittel und verfahren zu seiner herstellung.
EP2186902A3 (fr) Mise à l'échelle de polarisation de couple d'un côté sur l'autre afin d'améliorer la dérive dans une transmission à quatre roues motrices programmable
DE59101182D1 (de) Körpergewebeverträgliches Glas.
DK0725628T3 (da) Termisk geldannende lægemiddelindgivelsesvehikler indeholdende celluloseethere
WO1999064059A3 (fr) Utilisation de la secretine pour le traitement de l'autisme et d'autres troubles du comportement, troubles neurologiques ou immunologiques
NO20016304L (no) Erytropoetinkonjugater med polyetylenglykol, fremstilling av slike konjugater, preparater omfattende slike konjugater samt anvendelse av slike konjugater for fremstilling av medikamenter for forebygging eller behandling av sykdom
NL300253I2 (nl) Contrastmiddel voor diagnostische beeldvorming metverlengde retentie in bloed.
EP0388434A4 (en) Differential delivery of therapeutic agents across the blood brain barrier
KR920009419U (ko) 자동차의 앞부분 차체구조
DK360188A (da) Laegemiddelafgivelsesorgan
IT8920898A0 (it) Uso di sucralfato gel umido per il trattamento di ulcere del derma e come veicolo di farmaci ad attivita' topica.
NL187299B (nl) Gevormde farmaceutische doseringseenheid voor het behandelen van hart- en vaatziekten.
CA2091134A1 (fr) Agent therapeutique contre les risques d'avortement
MY110074A (en) Pharmacuetical formulation.
FR2572932B1 (fr) Medicament insoluble administre localement dans l'oreille
ATE108326T1 (de) Wässerige desmopressin-cmc enthaltende arzneizubereitung.
PT711163E (pt) Utilizacao de benzidamina no tratamento de estados patologicos provocados por tnf
ITRM930034A0 (it) Agente attivo per ridurre il livello ematico di glucocorticoidi e prevenire disturbi cerebrali da stress e senilita'.
NO20001895L (no) Anvendelse av glykosaminoglykaner for fremstilling av farmasøytiske preparater for behandling av diabetes assosierte- øyesykdommer
ZA947401B (en) Use of partially methylated beta-cyclodextrins as absorption promoters in the preparation of pharmaceutical compositions for the transcutaneous administration of active principles
SE8802323D0 (sv) 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it
Smith et al. 112 ELEVATION OF PROTHROMBIN FRAGMENT 1.2 IN PEDIATRIC CROHN'S DISEASE PATIENTS MAY BE ASSOCIATED WITH INCREASED THROMBOSIS RISK.
RU98106825A (ru) Средство для лечения герпетических заболеваний глаз
IT8609534A0 (it) Preparato,in particolare collirio o pomata,per il trattamento di alterazioni distrofiche e vascolari dei tessuti oculari.